Browse the evidence

Caloric restriction protects against induced carcinogenesis in mice, but this protective effect is entirely dependent on the Nrf2 pathway; without Nrf2, caloric restriction fails to suppress tumor development.

Caloric restriction is a powerful tool for cancer prevention, but its effectiveness relies on your body's ability to activate specific stress-response genes (Nrf2). If these genes are compromised, the cancer-protective benefits of calorie restriction may be lost, even if other benefits like insulin sensitivity remain.

Caloric restriction extends lifespan and improves insulin sensitivity in mice regardless of whether the Nrf2 pathway is functional.

Caloric restriction improves metabolic health and extends lifespan through mechanisms that do not rely on the Nrf2 stress-response pathway. This suggests that even if your Nrf2 system is compromised, you may still gain longevity and metabolic benefits from calorie restriction.

Elevated baseline serum levels of tyrosine and branched-chain/aromatic amino acids are strongly associated with a higher risk of incident type 2 diabetes in South Asian men, independent of obesity and insulin resistance measures.

For South Asian men, having higher levels of certain amino acids (like tyrosine and branched-chain amino acids) is a strong indicator of increased diabetes risk, even if you are not obese or insulin resistant. This suggests that metabolic health assessments should go beyond standard obesity measures. Regular monitoring of these markers, alongside lifestyle interventions focused on diet and physical activity, may help in early detection and prevention of type 2 diabetes.

African-American prepubertal children exhibit significantly lower insulin clearance and higher insulin secretion compared to American White children, resulting in hyperinsulinemia that is not merely a compensatory response to insulin resistance but involves an upregulated beta-cell function.

This research highlights that metabolic differences exist between racial groups, specifically regarding how insulin is cleared and secreted. For African-American children, these physiological differences may predispose them to higher insulin levels even with similar body composition to white peers. While this is a descriptive finding, it underscores the importance of monitoring metabolic health markers early. Dietary patterns, particularly the ratio of fat to carbohydrates, correlate with these metabolic rates, suggesting that nutritional interventions could potentially modulate these risks.

Conjugated linoleic acid (CLA) supplementation does not significantly influence blood lipid markers (total cholesterol, LDL, HDL, triacylglycerides) or blood pressure in humans, although it may increase C-reactive protein (CRP) without necessarily increasing cardiovascular disease risk.

Do not take CLA for the purpose of improving blood pressure or cholesterol levels. Clinical evidence shows it does not improve these cardiovascular risk markers in humans. Its primary utility remains modest body fat reduction.

Skeletal muscle acts as an endocrine organ that regulates systemic aging and lifespan through the secretion of myokines (e.g., IL-6, irisin, FGF-21) and metabolic adaptations, rather than solely through mechanical or mass-based effects.

Prioritize resistance training and aerobic exercise not just for muscle size, but to trigger the release of myokines like irisin and IL-6. These chemicals signal your liver, fat, and brain to improve metabolism and resist aging. Consistent movement is a chemical factory for longevity.

Myostatin inhibition increases muscle mass but does not protect against age-related sarcopenia or force decline, and may even worsen force development in aging.

Do not rely on myostatin inhibitors for anti-aging. Focus on exercise, which naturally regulates myostatin and improves function without the side effects of genetic manipulation.

Diet restriction increases hypothalamic SIRT1 levels, which activates dorsomedial and lateral hypothalamic nuclei to promote physical activity and maintain body temperature.

Diet restriction triggers a specific brain response (SIRT1 activation) that increases physical activity and maintains body temperature. This is an adaptive survival mechanism, not just a side effect.

SIRT1 upregulates orexin type 2 receptor (OX2R) expression in the hypothalamus, augmenting the response to ghrelin during diet restriction.

During diet restriction, your body increases ghrelin (hunger hormone). SIRT1 helps your brain respond to this by increasing orexin receptors, which drives activity and metabolism.

Inhibition of TXNIP expression or activity improves insulin sensitivity, protects pancreatic beta-cells from apoptosis, and ameliorates metabolic abnormalities in type 2 diabetes and obesity.

Targeting TXNIP is a promising therapeutic strategy for managing Type 2 Diabetes and obesity. Drugs like Metformin, GLP-1 agonists, and potentially repurposed drugs like Verapamil work partly by lowering TXNIP levels. This improves insulin sensitivity and protects pancreatic cells. However, because TXNIP helps maintain blood sugar during fasting, inhibitors must be carefully dosed to avoid hypoglycemia and potential long-term cancer risks associated with its loss.

SGLT1-mediated glucose uptake is the primary mechanism for early glucose-stimulated GLP-1 and GIP secretion, whereas metabolism-dependent pathways play a lesser role in peak early secretion.

Understanding that your gut senses glucose directly via transporters helps explain why whole foods trigger satiety hormones better than isolated sugars or sweeteners.

Bariatric surgery (specifically gastric bypass) leads to elevated levels of GLP-1 and PYY, which are linked to enhanced delivery of nutrients to the distal intestine and underlie beneficial outcomes on weight loss and glycemia.

Bariatric surgery works partly by changing how your gut senses food, leading to higher levels of satiety hormones like GLP-1 and PYY, which help with weight loss and blood sugar control.

Systemically administered GABAA receptor agonistic modulators (barbiturates, benzodiazepines, zolpidem, zopiclone, neuroactive steroids) reduce sleep latency, increase NREM sleep continuity, and promote sleep spindles, but suppress slow-wave activity (SWA) and REM sleep.

GABAA-targeting sleep medications (like benzodiazepines or Z-drugs) generally help you fall asleep faster and stay asleep longer by increasing NREM sleep and spindles. However, they tend to reduce deep slow-wave sleep and REM sleep. If sleep quality (depth and dreaming) is your priority, these drugs may alter your sleep architecture in ways that feel less restorative despite longer duration.

Selective GABAA agonists (muscimol, THIP) increase NREM sleep continuity and slow-wave activity (SWA) while attenuating spindle activity, suggesting a different physiological role for tonic vs phasic GABA receptor activation.

Unlike standard sleep aids that suppress deep sleep, direct GABAA agonists (like THIP) may increase deep slow-wave sleep and sleep continuity without necessarily speeding up sleep onset. This suggests that the *type* of GABA receptor activation (tonic vs phasic) dictates whether you get deep sleep or just sedation.

Higher baseline levels of Interleukin-6 (IL-6) and a steeper longitudinal increase in IL-6 levels are independently associated with an accelerated rate of developing multimorbidity (accumulation of chronic diseases) in older adults.

If you are over 60, monitoring inflammatory markers like IL-6 may help predict your risk of developing multiple chronic conditions. High or rising IL-6 levels are linked to a faster accumulation of diseases. This suggests that managing inflammation could be a key strategy to slow down the progression of multimorbidity in older adults.

Low levels of Dehydroepiandrosterone sulfate (DHEAS) are associated with a higher cross-sectional burden of multimorbidity in older adults.

Low levels of the hormone DHEAS are linked to having more chronic diseases in older adults. While not as strong a predictor of future disease progression as IL-6, low DHEAS is a marker of hormonal dysregulation associated with a higher burden of illness.

Specific inflammatory pathways (JNK, IKK/NF-κB, JAK/STAT) activated by macrophage-derived cytokines (TNF-α, IL-6, IL-1β) directly impair insulin signaling by causing serine phosphorylation of IRS-1.

Understanding that inflammation directly blocks insulin action at the cellular level highlights why anti-inflammatory strategies (like weight loss) are effective for improving insulin sensitivity.

Elevated local glucocorticoid activity in adipose tissue, driven by increased 11beta-HSD1 enzyme expression, causes visceral obesity and metabolic syndrome features despite normal circulating cortisol levels.

Visceral obesity is driven by local enzyme activity (11beta-HSD1) converting inactive steroids into active cortisol within belly fat, not necessarily by high blood cortisol. This suggests that therapies targeting this specific enzyme in adipose tissue could treat metabolic syndrome and visceral obesity without affecting systemic hormone levels.

Dietary restriction (caloric or nutrient restriction) extends lifespan by inactivating the TOR (Target of Rapamycin) pathway, which subsequently influences DAF-16/FOXO activity and mRNA levels.

Dietary restriction, such as caloric restriction, extends lifespan in model organisms by suppressing the TOR pathway. This suppression allows for the activation of DAF-16/FOXO, which regulates genes involved in longevity. This suggests that nutrient sensing is a critical lever for aging.

Activation of the AMP-activated protein kinase (AMPK) pathway extends lifespan and stress resistance by directly phosphorylating and activating DAF-16/FOXO.

AMPK, an energy sensor, extends lifespan by directly activating the DAF-16/FOXO transcription factor. This mechanism links cellular energy status (low glucose/high AMP) to longevity pathways.

Genetic variants in the FTO gene (specifically rs17817449 and rs1421085) are significantly associated with increased adiposity (BMI, weight, waist circumference) and insulin resistance, but these metabolic effects are mediated entirely by the increase in body fat rather than direct metabolic dysfunction.

If you have a family history of obesity, you likely carry genetic variants (like FTO) that make you prone to storing more fat. This doesn't mean you are powerless, but it does mean you may need to be more vigilant about energy balance than someone without these variants. Focus on maintaining a healthy body weight, as your genetic risk manifests primarily through increased adiposity rather than direct metabolic defects.

Infection and immune response actively alter sleep patterns, typically increasing slow-wave sleep (SWS) and decreasing REM sleep, which may be an adaptive mechanism to conserve energy for the immune response.

If you are sick, expect your sleep to change (more deep sleep, less REM). This is a normal, adaptive response by your body to fight the infection. Do not fight this sleepiness; allow your body to rest and recover.

Central administration of GLP-1 receptor agonists (GLP-1(7-36) amide or exendin-4) inhibits food and water intake in rats via hypothalamic glucose-sensing mechanisms, whereas peripheral administration has no acute effect on intake.

Central GLP-1 signaling strongly suppresses food and water intake in rats, while peripheral signaling does not. This suggests that for appetite suppression, the route of delivery and central receptor engagement are critical.

Genetic susceptibility interacts with environmental factors to influence obesity risk, where specific gene variants (e.g., beta-3 adrenergic receptor, UCP-1) affect energy expenditure and fat oxidation, but these genes only contribute to obesity when triggered by energy-dense diets and sedentary behavior.

If you have a family history of obesity, you may have genetic variants that make you more sensitive to high-calorie foods and inactivity. This doesn't mean you are doomed, but it means you need to be more vigilant about your diet and physical activity levels than someone without those genetic risks.